Form 4: Akero Therapeutics COO Jonathan Young Sells Shares to Cover Tax Obligations

Akero Therapeutics' Chief Operating Officer, Jonathan Young, sold 651 shares of common stock on March 13, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On March 13, 2024, Jonathan Young, the Chief Operating Officer of Akero Therapeutics, sold 651 shares of the company's common stock.
• The sale was executed at a price of $28.33 per share.
• This transaction was conducted to cover tax withholding obligations associated with the vesting of restricted stock units, in accordance with Akero Therapeutics' 'sell-to-cover' policy.
• Following the transaction, Young directly owns 268,306 shares of Akero Therapeutics.
• Young also has indirect ownership of 20,000 shares each through the EA Irrevocable Trust, CM Irrevocable Trust, and JL Irrevocable Trust, for the benefit of his children, with his spouse as trustee.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction (sell-to-cover) and doesn't inherently indicate positive or negative sentiment. It's a neutral event.

Positives

• The 'sell-to-cover' policy provides a mechanism for employees to manage tax obligations related to equity compensation.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential sentiment.

Stakeholder Impact

• The sale of shares by an insider could have a minor impact on shareholder sentiment, but the reason for the sale (tax obligations) mitigates potential negative interpretations.

Key Dates